论文部分内容阅读
目的:比较依达拉奉和舒血宁治疗急性脑梗死的最小成本。方法:86例急性脑梗死患者随机分为两组,在相同的常规治疗基础上,依达拉奉组40例给予依达拉奉注射液30 mg+0.9%氯化钠注射液100 ml,ivd bid;舒血宁组46例给予舒血宁注射液20ml+0.9%氯化钠注射液250ml,ivd qd,疗程均为两周。治疗后比较两组的成本-效果。结果:两组治疗后临床总有效率差异无统计学意义(P>0.05)。舒血宁组获得单位效果的成本最低。结论:从药物经济学角度出发,在常规治疗急性脑梗死的基础上,采用舒血宁注射液可获得较好疗效且医疗成本较低。
OBJECTIVE: To compare the minimal costs of edaravone and shuxuening in the treatment of acute cerebral infarction. Methods: Eighty-six patients with acute cerebral infarction were randomly divided into two groups. On the basis of the same routine treatment, edaravone was given to 40 cases of edaravone 30 mg + 0.9% sodium chloride injection 100 ml, ivd bid; Shuxuening 46 cases given Shuxuening injection 20ml + 0.9% sodium chloride injection 250ml, ivd qd, treatment for two weeks. After treatment, the cost-effectiveness of the two groups was compared. Results: There was no significant difference in the total effective rate between the two groups after treatment (P> 0.05). Shuxuening group to obtain the lowest unit cost. Conclusion: From the perspective of pharmacoeconomics, on the basis of conventional treatment of acute cerebral infarction, Shuxuening injection can achieve better efficacy and lower medical costs.